Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)Business Wire • 03/16/23
Merck & Co., Inc. (MRK) Barclays 2023 Global Healthcare Conference TranscriptSeeking Alpha • 03/16/23
MDA Breakout Stocks/ETFs Week 11 - March 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 03/12/23
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural MesotheliomaBusiness Wire • 03/10/23
Keytruda Who? Merck Nears Breakout On $10 Billion Sales Potential For Heart DrugsInvestors Business Daily • 03/07/23
Merck & Co., Inc. (MRK) Presents at Special Call (Investor Event at ACC.23/WCC) (Transcript)Seeking Alpha • 03/07/23
Merck's Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background TherapyBusiness Wire • 03/06/23
Merck's MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b StudyBusiness Wire • 03/06/23
US FDA Approves Intramuscular Administration for Merck's MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)Business Wire • 03/06/23
MDA Breakout Stocks Week 10 - March 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 03/05/23
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate CancerBusiness Wire • 03/02/23
Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung CancerBusiness Wire • 03/01/23